The CRC Digest

Curated CRC research — accessible, accurate, actionable

Saturday, March 21, 2026

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

• Phase II trial compares FOLFIRI plus ramucirumab to FOLFOXIRI plus ramucirumab for first-line metastatic CRC

  Japanese randomized trial (WJOG9216G/RECAST) evaluated two first-line treatment combinations for metastatic colorectal cancer, comparing standard FOLFIRI with intensified FOLFOXIRI, both combined with ramucirumab. Study results are now available. (European Journal of Cancer)

• COLONPREV study characterizes differences in precancerous lesions detected by colonoscopy versus FIT screening

  Spanish researchers analyzed characteristics of premalignant lesions found through colonoscopy screening compared to fecal immunochemical test (FIT) screening, providing insights into how different screening methods detect early abnormalities. (Gastroenterology)

• CT-based radiomics model may help identify stage II pMMR patients who benefit from adjuvant chemotherapy

  Study of 379 stage II proficient mismatch repair (pMMR) colorectal cancer patients developed a CT imaging-based model to predict prognosis and potentially guide decisions about adjuvant chemotherapy in this group where treatment benefit is uncertain. (Abdominal Radiology)

• Meta-analysis examines effectiveness of exercise during adjuvant chemotherapy for colorectal cancer

  Systematic review analyzed multiple studies on exercise interventions specifically during adjuvant chemotherapy for colorectal cancer patients, aiming to clarify whether exercise provides measurable benefits during this treatment phase. (Supportive Care in Cancer)

Research continues to refine treatment decisions and screening approaches across the colorectal cancer care continuum.

The CRC Digest

Research intelligence for the colorectal cancer community

Content is curated with AI assistance and reviewed by the editorial team.

Read our full disclaimer

Unsubscribe